Q5126 Bevacizumab-maly - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Bevacizumab-maly

Brand Name:

Alymsys

Strength:

10mg

HCPCS:

Q5126

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

VEGF

Oral (Y/N):

No

FDA Approval Year:

2022

FDA Discontinuation Year:

CMS Effective Date:

Nov. 28, 2022

CMS Discontinuation Date:

Status:

In Use